Transmission of the X4 phenotype of HIV-1: Is there evidence against the "random transmission" hypothesis?

Journal of Infectious Diseases

Volumn 205, Issue 2, 2012, Pages 163-165

  Hedskog, Charlotte ^a   Mild, Mattias ^a   Albert, Jan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MARAVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; FALSE POSITIVE RESULT; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR PHYLOGENY; NONHUMAN; NOTE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PYROSEQUENCING; VIRUS ENTRY; VIRUS TRANSMISSION;

FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; VIRAL TROPISM;

EID: 84555195615     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir719     Document Type: Note

References (32)

1. A ° sjö B, Morfeldt-Ma°nson L, Albert J, et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986; 2:660-2. (Pubitemid 16029378)
2. Tersmette M, de Goede RE, Al BJ, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDSrelated complex. J Virol 1988; 62:2026-32.
3. Koot M, Vos AH, Keet RP, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992; 6:49-54.
4. Fiore JR, Björndal A, Peipke KA, et al. The biological phenotype of HIV-1 is usually retained during and after sexual transmission. Virology 1994; 204:297-303. (Pubitemid 24305342)
5. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993; 7:1035-40. (Pubitemid 23246445)
6. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD41 cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8. (Pubitemid 23118038)
7. Karlsson A, Parsmyr K, Sandström E, Fenyö EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994; 32: 364-70. (Pubitemid 24033896)
8. Schuitemaker H, van 't Wout AB, Lusso P. Clinical significance of HIV-1 coreceptor usage. J Transl Med 2011; 9(Suppl 1):S5.
9. Grivel JC, Shattock RJ, Margolis LB. Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med 2011; 9(Suppl 1):S6.
10. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185: 621-8. (Pubitemid 27098147)
11. Raymond S, Delobel P, Mavigner M, et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 2010; 24: 2305-12.
12. Frange P, Chaix ML, Raymond S, et al. Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol 2010; 48: 3487-91.
13. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105:7552-7. (Pubitemid 351830056)
14. de Mendoza C, Rodriguez C, Garcia F, et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007; 59:698-704. (Pubitemid 47073404)
15. Raymond S, Saliou A, Nicot F, et al. Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing. AIDS 2011; 25:1668-70.
16. Abbate I, Vlassi C, Rozera G, et al. Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 2011; 25:611-17.
17. Archer J, Braverman MS, Taillon BE, et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009; 23:1209-18.
18. Bunnik EM, Swenson LC, Edo-Matas D, et al. Detection of inferred CCR5-and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog 2011; 7:e1002106.
19. Swenson LC, Mo T, Dong WW, et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203:237-45.
20. Low AJ, Marchant D, Brumme CJ, et al. CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Hum Retroviruses 2008; 24:219-28. (Pubitemid 351282100)
21. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS 2008; 22:1425-31.
22. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-74. (Pubitemid 41023125)
23. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25: 1407-10. (Pubitemid 350233143)
24. Jensen MA, Li FS, van 't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77:13376-88. (Pubitemid 37494331)
25. Holmes EC. RNA virus genomics: a world of possibilities. J Clin Invest 2009; 119:2488-95.
26. Chalmet, et al. "Article title." J Infect Dis 2011; 205:174-84.
27. Saliou A, Delobel P, Dubois M, et al. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 2011; 55:2831-6.
28. Vandekerckhove LP, Wensing AM, Kaiser R, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11:394-407.
29. Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785-92. (Pubitemid 38657214)
30. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-93.
31. Herbeck JT, Rolland M, Liu Y, et al. Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol 2011; 85:7523-34.
32. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-89.